个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Novel TYK2 inhibitor D-2570 in moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 2 trial

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：

收录情况： ◇ 自然指数

作者：
Zhang Jianzhong[1,*1] * ; Zhou Cheng[2] ; Miao Guoying[3] ; Zhang Shoumin[4] ; Duan Xinsuo[5] ; Wu Liming[6] ; Zhang Guoqiang[7] ; Dang Ningning[8] ; Ding Yangfeng[9] ; Han Hongfang[10] ; Wei Aihua[11] ; Yang Bin[12] ; Li Linfeng[13] ; Li Shanshan[14] ; Dai Xunyi[15] ; Zhang Jianglin[16] ; Lei Tiechi[17] ; Yan Wenjie[18] ; Zhang Lixia[19] ; Meng Zudong[20] ; Chen Rixin[21] ; Song Qiuhe[22] ; Wang Liangchun[23] ; Wang Wenhui[24] ; Hu Xinglin[25] ; Xiang Ziyong[26] ; Shi Zhe[26] ; Zhang Ling[26] ;
机构： [1]Department of Dermatology, Peking University People's Hospital, Beijing, China. Electronic address: rmzjz@126.com. [2]Department of Dermatology, Peking University People's Hospital, Beijing, China. [3]Department of Dermatology, Affiliated Hospital of Hebei University of Engineering, Handan, China. [4]Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou, China. [5]Department of Dermatology, Affiliated Hospital of Chengde Medical University, Chengde, China. [6]Department of Dermatology, Hangzhou First People's Hospital, Hangzhou, China. [7]Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang, China. [8]Department of Dermatology, Shandong Provincial Hospital, Jinan, China. [9]Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China. [10]Department of Dermatology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. [11]Department of Dermatology, Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, China. [12]Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China. [13]Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. [14]Department of Dermatology, First Hospital of Jilin University, Changchun, China. [15]Department of Dermatology, Wuxi Second People's Hospital, Wuxi, China. [16]Department of Dermatology, Shenzhen People's Hospital, Shenzhen, China. [17]Department of Dermatology, RenMin Hospital of Wuhan University, Wuhan, China. [18]Department of Dermatology, The Affiliated Hospital of Guilin Medical University, Guilin, China. [19]Department of Dermatology, Sichuan Provincial People's Hospital, Chengdu, China. [20]Department of Dermatology, Shiyan Renmin Hospital, Shiyan, China. [21]Department of Dermatology, Nanyang First People's Hospital, Nanyang, China. [22]Department of Dermatology, Jiujiang University Affiliated Hospital, Jiujiang, China. [23]Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. [24]Department of Dermatology, Peking University Third Hospital, Beijing, China. [25]Department of Dermatology, The First People's Hospital of Chenzhou, Chenzhou, China. [26]InventisBio Co., Ltd, Shanghai, China.
出处：
DOI： 10.1016/j.jaad.2025.09.036
ISSN：

摘要：
D-2570, a TYK2 inhibitor, is currently being developed for autoimmune diseases including psoriasis and ulcerative colitis.To evaluate the efficacy and safety of D-2570 in patients with moderate-to-severe plaque psoriasis.In the randomized, double-blind, phase 2 study (NCT06278350), patients were randomized 1:1:1:1 to receive D-2570 at 18/27/36 mg, or placebo once daily for 12 weeks. The primary endpoint was the proportion of patients achieving psoriasis area severity index (PASI) 75 at week 12. Secondary endpoints included PASI 75/90/100 and static Physician Global Assessment (sPGA) score of 0/1, safety, and pharmacokinetic/pharmacodynamic characteristics.At week 12, significantly higher response rates for PASI 75 (85.0%-90.0%, vs 12.5%, p<0.001 for all), PASI 90 (70.7%-77.5% vs 5.0%, p<0.001), PASI 100 (39.0%-50.0% vs 2.5%, p<0.005) and sPGA 0/1 (80.5%-87.5% vs 20.0%, p<0.001) were achieved in patients receiving D-2570 at 18/27/36 mg versus placebo. D-2570 was well tolerated, and most treatment-emergent adverse events were mild/moderate. D-2570 exhibited favorable pharmacokinetic properties and effectively suppressed IL-17A levels in patients.small sample size, relatively short duration of treatment and follow-up.D-2570 demonstrated a high efficacy with favorable safety profile in patients with moderate to severe plaque psoriasis.Copyright © 2025. Published by Elsevier Inc.

语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 1 区 医学
小类 | 1 区 皮肤病学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 皮肤病学
第一作者：
第一作者机构： [1]Department of Dermatology, Peking University People's Hospital, Beijing, China. Electronic address: rmzjz@126.com. [*1]Department of Dermatology, Peking University People’s Hospital, No.11 Xizhimen South St, Beijing, China
通讯作者：
通讯机构： [1]Department of Dermatology, Peking University People's Hospital, Beijing, China. Electronic address: rmzjz@126.com. [*1]Department of Dermatology, Peking University People’s Hospital, No.11 Xizhimen South St, Beijing, China
推荐引用方式(GB/T 7714)：
Zhang Jianzhong,Zhou Cheng,Miao Guoying,et al.Novel TYK2 inhibitor D-2570 in moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 2 trial[J].Journal Of The American Academy Of Dermatology.2025,doi:10.1016/j.jaad.2025.09.036.
APA：
Zhang Jianzhong,Zhou Cheng,Miao Guoying,Zhang Shoumin,Duan Xinsuo...&Zhang Ling.(2025).Novel TYK2 inhibitor D-2570 in moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 2 trial.Journal Of The American Academy Of Dermatology,,
MLA：
Zhang Jianzhong,et al."Novel TYK2 inhibitor D-2570 in moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 2 trial".Journal Of The American Academy Of Dermatology .(2025)

资源点击量：29032 今日访问量：0 总访问量：1619 更新日期：2025-10-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持：重庆聚合科技有限公司 地址：北京市东城区东交民巷1号(100730)